Zynex logo

ZynexNASDAQ: ZYXI

Profile

Sector:

Healthcare

Country:

United States

IPO:

25 February 2004

Next earnings report:

28 February 2025

Last dividends:

05 January 2022

Next dividends:

N/A
$244.89 M
-60%vs. 3y high
57%vs. sector
-17%vs. 3y high
81%vs. sector
-44%vs. 3y high
88%vs. sector
-71%vs. 3y high
28%vs. sector

Price

after hours | 82 min ago
$7.69-$0.08(-1.03%)
$49.97 M$53.65 M
$49.97 M$2.38 M

Analysts recommendations

Institutional Ownership

ZYXI Latest News

Zynex Inc. (ZYXI) Tops Q3 Earnings Estimates
zacks.com24 October 2024 Sentiment: POSITIVE

Zynex Inc. (ZYXI) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.10 per share a year ago.

Zynex sees pain management orders increase in Q3 following FDA approval
proactiveinvestors.com24 October 2024 Sentiment: POSITIVE

Zynex Inc (NASDAQ:ZYXI) announced its third-quarter 2024 financial and operational results highlighted by a 13% year-over-year increase in orders. The pain management device company reported net revenue of $50 million for the quarter ended September 30, 2024, up slightly from $49.9 million in the prior-year period.

Zynex Reports Third Quarter 2024 Financial Results
prnewswire.com24 October 2024 Sentiment: POSITIVE

ENGLEWOOD, Colo. , Oct. 24, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the third quarter ended September 30, 2024.

Zynex Sets Third Quarter 2024 Earnings Call
prnewswire.com16 October 2024 Sentiment: POSITIVE

ENGLEWOOD, Colo. , Oct. 16, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, October 24, 2024 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended September 30, 2024.

Zynex's strategic shifts set stage for long-term success, analysts say
proactiveinvestors.com16 September 2024 Sentiment: POSITIVE

Analysts expect Zynex Inc (NASDAQ:ZYXI) to return to stronger growth in 2025, driven by product diversification, sales force expansion, and upcoming product launches. The company's strategic initiatives are seen as laying the groundwork for long-term success despite short-term hurdles.

Zynex CEO reflects on 28 years of medical device innovation - ICYMI
proactiveinvestors.com07 September 2024 Sentiment: POSITIVE

Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard recently sat down with Proactive to discuss the medical device company's innovative solutions and impressive growth trajectory.   Sandgaard highlighted how Zynex has expanded from a one-person operation 28 years ago to a company with 1,200 employees and revenues reaching $200 million.

Zynex Stock Rises on FDA Clearance of Its New Pain Management Device
zacks.com04 September 2024 Sentiment: POSITIVE

ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.

Zynex to Present at the HC Wainwright Global Investment Conference
prnewswire.com04 September 2024 Sentiment: POSITIVE

ENGLEWOOD, Colo. , Sept. 4, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming HC Wainwright Global Investment Conference, which is being held September 9-11, 2024.

Zynex pain management device TensWave achieves FDA clearance
proactiveinvestors.com03 September 2024 Sentiment: POSITIVE

Zynex Inc (NASDAQ:ZYXI) announced that its portable pain management device TensWave has achieved Food and Drug Administration (FDA) clearance. The prescription-only TensWave device aims to provide pain relief through TENS (Transcutaneous Electrical Nerve Stimulation) therapy, which the company highlighted has been clinically proven to reduce chronic and acute pain without needing medication.

Zynex Obtains FDA clearance for new Pain Management Device
prnewswire.com03 September 2024 Sentiment: POSITIVE

ENGLEWOOD, Colo. , Sept. 3, 2024 /PRNewswire/ -- Zynex Inc. (NASDAQ: ZYXI), a leading medical technology company specializing in non-invasive medical devices for pain management and rehabilitation, today announced FDA clearance of its new TensWave device.

  • 1(current)
  • 2

What type of business is Zynex?

Zynex, Inc. is a manufacturer of medical equipment specializing in electrotherapeutic devices used in pain management, physical rehabilitation, neurological diagnostics, and cardiac monitoring. The company was founded in 1996 and is headquartered in Englewood, Colorado. The company designs, manufactures, and sells its own medical devices through three subsidiaries: Zynex Medical provides products for home use electrotherapy. Zynex Monitoring Solutions develops heart monitoring products for hospital use. Zynex NeuroDiagnostics develops EMG and EEG diagnostic devices for neurological clinics.

What sector is Zynex in?

Zynex is in the Healthcare sector

What industry is Zynex in?

Zynex is in the Medical Distribution industry

What country is Zynex from?

Zynex is headquartered in United States

When did Zynex go public?

Zynex initial public offering (IPO) was on 25 February 2004

What is Zynex website?

https://www.zynex.com

Is Zynex in the S&P 500?

No, Zynex is not included in the S&P 500 index

Is Zynex in the NASDAQ 100?

No, Zynex is not included in the NASDAQ 100 index

Is Zynex in the Dow Jones?

No, Zynex is not included in the Dow Jones index

When was Zynex the previous earnings report?

No data

When does Zynex earnings report?

The next expected earnings date for Zynex is 28 February 2025